Literature DB >> 12717052

Drug Resistance Mutations in HIV-1.

Richard T. D'Aquila1, Jonathan M. Schapiro, Françoise Brun-Vézinet, Bonaventura Clotet, Brian Conway, Lisa M. Demeter, Robert M. Grant, Victoria A. Johnson, Daniel R. Kuritzkes, Clive Loveday, Robert W. Shafer, Douglas D. Richman.   

Abstract

Entities:  

Year:  2002        PMID： 12717052

Source DB:  PubMed          Journal:  Top HIV Med        ISSN： 1542-8826


× No keyword cloud information.
  15 in total

1.  Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Authors:  F Damond; F Brun-Vezinet; S Matheron; G Peytavin; P Campa; S Pueyo; F Mammano; S Lastere; I Farfara; F Simon; G Chene; D Descamps
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

2.  A study of the interaction between HIV-1 protease and C 2-symmetric inhibitors by computational methods.

Authors:  Shuhua Shi; Guodong Hu; Xiumei Zhang; Jihua Wang
Journal:  J Mol Model       Date:  2014-07-15       Impact factor: 1.810

3.  High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.

Authors:  Francesca Ceccherini-Silberstein; Federico Gago; Maria Santoro; Caterina Gori; Valentina Svicher; Fátima Rodríguez-Barrios; Roberta d'Arrigo; Massimo Ciccozzi; Ada Bertoli; Antonella d'Arminio Monforte; Jan Balzarini; Andrea Antinori; Carlo-Federico Perno
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

Authors:  Xiaoqing Liu; Zhilong Xiu; Ce Hao
Journal:  J Comput Aided Mol Des       Date:  2009-02-15       Impact factor: 3.686

5.  Abacavir/lamivudine combination in the treatment of HIV: a review.

Authors:  Geetha Sivasubramanian; Emmanuel Frempong-Manso; Rodger D Macarthur
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

6.  Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).

Authors:  Claudia Reinheimer; Anna Wesner; Oliver T Keppler; Hans Wilhelm Doerr; Eva Herrmann; Martin Stürmer; Christoph Stephan
Journal:  Med Microbiol Immunol       Date:  2016-01-08       Impact factor: 3.402

7.  Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.

Authors:  Bradley C Logsdon; John F Vickrey; Philip Martin; Gheorghe Proteasa; Jay I Koepke; Stanley R Terlecky; Zdzislaw Wawrzak; Mark A Winters; Thomas C Merigan; Ladislau C Kovari
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil.

Authors:  Ivone L Pires; Marcelo A Soares; Francisco A B Speranza; Solange K Ishii; Maria C G Vieira; Maria I F S Gouvêa; Maria A A M Guimarães; Fátima E de Oliveira; Monica M F Magnanini; Rodrigo M Brindeiro; Amilcar Tanuri
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

9.  Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

Authors:  Haili Zhang; Yan Zhou; Cecily Alcock; Tara Kiefer; Daphne Monie; Janet Siliciano; Quan Li; Paul Pham; Joseph Cofrancesco; Deborah Persaud; Robert F Siliciano
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Host sequence motifs shared by HIV predict response to antiretroviral therapy.

Authors:  William Dampier; Perry Evans; Lyle Ungar; Aydin Tozeren
Journal:  BMC Med Genomics       Date:  2009-07-23       Impact factor: 3.063
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.